-
Mashup Score: 3
The Post-ASH 2021 iwAL Virtual Meeting will be held on 20th and 21st January 2022. The program will cover ALL and MDS on Day 1 and AML on Day 2, with a series of short presentations from invited experts on selected abstracts from the 63rd ASH Annual Meeting, with interactive panel discussions after each session. Applying for registration: This event is for hematologists, researchers, nurses,…
Source: Zoom Video CommunicationsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Mutations in in fms-like tyrosine kinase 3 (FLT3) gene are common genomic alterations in acute myeloid leukemia (AML). FLT3 internal tandem duplication mutations (FLT3-ITD) have consistently been sho…
Source: Wiley Online LibraryCategories: Hem/Oncs, Latest HeadlinesTweet-
👉👉👉New paper from our group led by @patrickreville & @TapKadia 💥 Improved Outcomes Among Newly Diagnosed Patients w/ #FLT3‐ITD Mutated AML Treated w/ Contemporary Therapy https://t.co/hqef3rFEHp | @DrHKantarjian @musayilmaz54 @Daver_Leukemia @JoeKhouryMD @garciamanero #leusm
-
-
Mashup Score: 0Meeting Library | Meeting Library - 4 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2021 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
#ASCO21 @ASCO || #Quizartinib w/ #decitabine & #venetoclax (triplet) is highly active in patients w/#FLT3-ITD AML| led by @musayilmaz54 & @Daver_Leukemia | @TapKadia @DrHKantarjian @garciamanero #leusm https://t.co/EJ9qbzkKdV
-
-
Mashup Score: 2Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors - 4 year(s) ago
Despite promising results with FLT3 inhibitors (FLT3i), response durations remain short. We studied pretreatment and relapse bone marrow samples from patients with FLT3 -mutated acute myeloid leukemia (AML) treated with FLT3i-based therapies (secondary resistance cohort), and pretreatment bone marrow samples from patients with no response to FLT3i-based therapies (primary resistance cohort)….
Source: Blood Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet-
Patterns of Resistance Differ in Patients with AML Treated with Type I versus Type II #FLT3 Inhibitors | @BCD_AACR Led by @AAlotaibi_MD & @Daver_Leukemia | @kanagalshamanna @sanamloghavi @doctorpemm #leusm https://t.co/wDJoJSBuID
-
-
Mashup Score: 1
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Study Sets Response Benchmarks for FLT3‐Inhibitor Sequencing in FLT3‐Mutated AML #ASH2020 #AML #FLT3 https://t.co/T3M8LcN4OH https://t.co/gNP6Tp1DE2
-
-
Mashup Score: 1Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3‐Mutated AML - 4 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3‐Mutated AML #ASH2020 #AML #FLT3 https://t.co/ki26pzsmDu https://t.co/OvWMKDm8r9
-
-
Mashup Score: 0Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia - PubMed - 4 year(s) ago
We evaluated standard-of-care (SOC) treatment with or without midostaurin to prevent relapse following allogeneic hematopoietic stem cell transplant (alloHSCT) in patients with acute myeloid leukemia (AML) harboring internal tandem duplication (ITD) in FLT3. Adults (aged 18-70 years) who received al …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute … https://t.co/fl4v9nHbvN @MayoCancerCare @MRLitzow #FLT3
-
-
Mashup Score: 1Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3‐ITD and IDH mutations - 5 year(s) ago
The combination of FMS‐like tyrosine kinase 3 (FLT3) inhibitor–based therapy with high‐intensity and/or intermediate‐intensity conventional cytotoxic chemotherapy or low‐intensity regimens appears to…
Source: American Cancer Society JournalsCategories: Hem/Oncs, Latest HeadlinesTweet-
👉👉👉 Clinical outcomes in patients w/AML & concurrent #FLT3& #IDH mutations➡️Led by Dr Daver&Dr Shoukier https://t.co/800e4kfNev | @Daver_Leukemia @TapKadia @AAlotaibi_MD @Malfayez7 @sanamloghavi @kanagalshamanna @GCC_Cortes @garciamanero @DrKTakahashi @JournalCancer #leusm
-
-
Mashup Score: 3
Second-generation FLT3-inhibitors (FLT3i) demonstrated single-agent composite CR rates (CRc) of 45–55% in patients with relapsed/refractory (R/R) FLT3-mutated AML in phase II/III trials. However, > 85% of patients treated were prior FLT3i naïve. The response rates to sequential FLT3i exposure remain poorly defined. We retrospectively reviewed patients with FLT3-mutated AML between November 2006…
Source: Journal of Hematology & OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
👉👉👉Our group’s new paper led by @musayilmaz54 & Dr Daver ➡️ Outcomes w/sequential #FLT3-inhibitor-based therapies in patients w/AML | @Malfayez7 @TapKadia @sanamloghavi @kanagalshamanna #leusm #endcancer https://t.co/GHcy4robwn
-
-
Mashup Score: 1First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations - 5 year(s) ago
The prognostics implications of patients with acute myeloid leukemia harboring non-canonical FLT3 is unknown. The use of tyrosine kinase inhibitors in this patient population has not been previously reported. We report successful targeted therapy against non-ITD, non-D835 driver FLT3 alterations in two patient case studies with acute myeloid leukemia.
Source: FrontiersCategories: Hem/Oncs, Latest HeadlinesTweet-
👉👉👉Hot off the press our group’s latest report ➡️ First Report of #Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical #FLT3 Mutations https://t.co/AejF8XKyts | @Daver_Leukemia @allydprice @DrKTakahashi @doctorpemm @LeukemiaMDA #leusm #endcancer
-
post-ASH #iwAL Virtual Workshop | panel discussion on #FLT3 Featuring presentations & discussions on selected abstracts in #AML from the 63rd ASH Annual Meeting Tune in here: https://t.co/pF1x4cjLUX #Leusm #MDSsm #AMLsm #ALLsm https://t.co/7ompn5jyuS